Results 11 to 20 of about 111,058 (316)
Lung Cancer Management, 2016 In the era of high-throughput molecular screening and personalized medicine, difficulty in determining whether cancer mutations are truly 'actionable' remains a gray zone in NSCLC. The most important prerequisite to perform such investigations is the tumor tissue retrieval via biopsy at diagnosis and after occurrence of resistance.
Trombetta, D. +3 more
openaire +2 more sources
Liquid biopsies and cancer omics [PDF]
Cell Death Discovery, 2020 AbstractThe development of the sequencing technologies allowed the generation of huge amounts of molecular data from a single cancer specimen, allowing the clinical oncology to enter the era of the precision medicine. This massive amount of data is highlighting new details on cancer pathogenesis but still relies on tissue biopsies, which are unable to ...
Yufang Shi +25 more
openaire +6 more sources
Oncogenesis, 2023 AIFM2 is a crucial NADH oxidase involved in the regulation of cytosolic NAD+. However, the role of AIFM2 in the progression of human cancers remains largely unexplored.
Sanxing Guo +14 more
doaj +1 more source
Liquid biopsies: Potential and challenges [PDF]
International Journal of Cancer, 2020 AbstractThe analysis of tumor cells or tumor cell products obtained from blood or other body fluids (“liquid biopsy” [LB]) provides a broad range of opportunities in the field of oncology. Clinical application areas include early detection of cancer or tumor recurrence, individual risk assessment and therapy monitoring.
Heidrich, Isabel +3 more
openaire +3 more sources
Liquid Biopsy in Neurological Diseases
Cells, 2023 The most recent and non-invasive approach for studying early-stage biomarkers is liquid biopsy. It implies the extraction and analysis of non-solid biological tissues (serum, plasma, saliva, urine and cerebrospinal fluid) without undergoing invasive procedures to determine disease prognosis.
Sunny Malhotra +4 more
openaire +4 more sources
Emerging concepts in liquid biopsies [PDF]
BMC Medicine, 2017 Characterizing and monitoring tumor genomes with blood samples could achieve significant improvements in precision medicine. As tumors shed parts of themselves into the circulation, analyses of circulating tumor cells, circulating tumor DNA, and tumor-derived exosomes, often referred to as "liquid biopsies", may enable tumor genome characterization by ...
Perakis, Samantha; Speicher, Michael R.
openaire +4 more sources
Frontiers in Molecular Biosciences, 2021 The high incidence and mortality of lung cancer make early detection of lung cancer particularly important. At present, the diagnosis of lung cancer mainly depends on diagnostic imaging and tissue biopsy. However, current diagnostics are not satisfactory
Lanxiang Huang +11 more
doaj +1 more source
Cell Death and Disease, 2021 TEFM (transcription elongation factor of mitochondria) has been identified as a novel nuclear-encoded transcription elongation factor in the transcription of mitochondrial genome.
Lixin Wan +11 more
doaj +1 more source
Molecular Oncology, 2021 Despite impressive and durable responses, nonsmall cell lung cancer (NSCLC) patients treated with anaplastic lymphoma kinase (ALK) inhibitors (ALK‐Is) ultimately progress due to development of resistance.
Estela Sánchez‐Herrero +17 more
doaj +1 more source
Liquid Biopsy in Gastrointestinal Cancers [PDF]
Diagnostics, 2018 Liquid biopsy is the sampling of any biological fluid in an effort to enrich and analyze a tumor’s genetic material. Peripheral blood remains the most studied liquid biopsy material, with circulating tumor cells (CTC’s) and circulating tumor DNA (ctDNA) allowing the examination and longitudinal monitoring of a tumors genetic landscape.
Aman Saini +7 more
openaire +4 more sources